Aim During the last decade, treatment protocols have changed for patients with ileocolic Crohn's disease. Antitumour necrosis factor (anti-TNF) has become part of standard medical treatment, usually in a step-up approach. The aim was to analyse if improved medical treatment has resulted in more limited ileocolic resections and a longer interval between diagnosis and surgery.
Introduction
Crohn's disease (CD) is a relatively common chronic disease of the gastrointestinal tract. Eventually, 70%-80% of Crohn's patients used to require surgery [1] . Patients with ileocolic CD are usually treated according to the guidelines issued by the European Crohn's and Colitis Organization [2] . Treatment of these patients consists primarily of medical therapy including (systemic) steroids and immunomodulators. In 1999, anti-tumour necrosis factor (anti-TNF) was introduced for CD and administered depending on the patients' clinical characteristics, previous response to other medical therapies, disease phenotype and comorbid conditions. With this new drug, patients who were previously nonresponsive to immunomodulating or other therapies could now be treated, aiming at avoiding or postponing surgery.
In a recent study from Denmark, an increase of the use of immunomodulators and biologicals was observed between 1979 and 2011. This was associated with a reduction in the proportion of patients who required surgery during this period [3] . Whether this merely reflects postponed resections and whether this is entirely caused by improved medical treatment is unclear. In addition, it has been hypothesized that the length of resected small bowel might be reduced by the more recently optimized medical treatment algorithms, e.g. that more intensive medical treatment is bowel sparing. The aim of this study was to analyse whether the availability of better drugs and improved medical treatment protocols including anti-TNF has influenced surgical strategies resulting in a longer delay between diagnosis and surgery and more limited resections.
Method
In a retrospective cohort study, adult patients undergoing primary ileocolic resection for CD in the Academic Medical Centre (AMC) between January 1999 and October 2014 were identified from a prospectively maintained database. To gain insight into the background population of this study population, a recent population-based cohort in the catchment area of three teaching hospitals that usually refer patients to the Academic Medical Centre was used for comparison [4] . In this population-based study, the prevalence and incidence of inflammatory bowel disease (IBD) were assessed between 2004 and 2010. For the comparison with this population-based cohort, which was considered most representative for the present study, new end-points that were not previously published in the study by de Groof et al. were assessed. The hospital catchment area of the three teaching hospitals covered an average of 319 976 adult inhabitants during the study period, and 1461 IBD patients were identified of whom 579 were CD patients.
Inclusion criteria
Adult patients undergoing their first ileocolic resection for ileocaecal CD were included with the exception of patients included in the LIR!C trial (NTR1150, Laparoscopic ileocolic resection vs infliximab treatment of recurrent distal ileitis in Crohn's disease: a randomized multicentre trial) who were randomized to primary ileocolic resection. These patients were excluded to avoid bias by undergoing earlier resection than protocol treatment, since surgical resection is still currently considered second line therapy [2, 5] . No patients were included after October 2014 since at that time a study was initiated in the Academic Medical Centre where parts of the resection specimen were used for basic research purposes directly postoperatively. Therefore the correct length of the resection specimen could not be measured in the Department of Pathology.
Study parameters
The end-points of this study were changes over time in the preoperative medication regimen, the time between CD diagnosis and ileocolic resection and the length of the resected ileum. The length of the resection specimen was measured immediately postoperatively at the Department of Pathology according to a standard protocol. Data on age, sex, body mass index, date of diagnosis, date of surgery, preoperative medical treatment for CD, indication for surgery and preoperative and postoperative complications (e.g. conversion to open surgery, stoma creation and surgical re-interventions) were obtained from the medical records. Azathioprine, 6-mercaptopurine and methotrexate were designated as immunomodulators and infliximab and adalimumab as anti-TNF. Medication use was reported as use ever prior to surgery. Missing data were reported and no data imputation was performed.
Statistical analysis
Data are presented as median and interquartile range (IQR) in non-parametric data and as mean and standard deviation (SD) in the case of parametric data. The Mann-Whitney U test was used for comparing nonparametric data. Correlation between the date of ileocolic resection and time between diagnosis (in months) of CD ileocolic resection as well as the correlation between the length of resected ileum (in cm) and date of ileocolic resection were assessed by means of Spearman's correlation and linear regression analysis. A P value < 0.05 was considered significant. SPSS statistics for Windows (version 22, IBM Corp., Armonk, New York, USA) was used for data collection and statistical analysis. The Cochrane-Armitage trend test was used to evaluate change in anti-TNF and immunomodulator use over time (statistical program R for Windows version 3.0.2 â Foundation, Vienna, Austria).
Results

Patient characteristics
During the study period, 613 ileocolic resections were performed. In total 195 patients remained for the present study after exclusion of 418 patients for various reasons (Fig. 1) . Baseline characteristics are reported in Table 1 . In total, 131 procedures were performed laparoscopically of which 29 were via single port. Sixtythree patients were men (32.3%) and the median age at time of surgery was 30.0 years (IQR 23.0-40.0). The main indications for surgery were fibrotic stenosis of the terminal ileum and therapy-refractory disease (47.2%, 95% CI: 40.3-54.2, and 38.5%, 95% CI: 31.9-45.5, respectively). Surgical and pathology data are reported in Table 2 . When grouped by anti-TNF use, the median age at diagnosis and age at surgery were comparable ( Table 3 ). The indication for surgery did not differ significantly between patients with or without anti-TNF treatment (P = 0.29). Patient characteristics, e.g. median age at surgery, were comparable between the population-based data and the patients in the present study, confirming a representative study group (Table 4) .
Medical therapy
The majority of patients were treated medically with steroids (67.7%, 95% CI: 60. 
Time to surgery
Over the years, a significant increase in the time interval from diagnosis to surgery was found [overall median 39.0 months; rho 0.175, P = 0.01; regression coefficient 3.38 (95% CI: 1.18-5.57), P = 0.003] (Fig. 3) . When grouped by anti-TNF use, a median time to surgery of 61 months (IQR 25.0-101.0) was observed for patients with anti-TNF compared to 29 months (IQR 10.0-68.5) in patients without anti-TNF treatment. This was significantly different between the two groups (P = 0.005; Table 3 ).
Length of resection specimen
No significant decrease in the length of the resected ileum was found during the study period [median (Table 3 ). This was not significantly different (P = 0.87). Of the 195 patients, 16 patients (8.2%, 95% CI: 5.1-12.9) underwent a resection of the neoterminal ileum after a mean time of 61.8 months (AE8.6), with a median length of the resected ileum of 13.0 cm (IQR 7.0-18.0). The majority of these 16 patients (n = 15) were treated with anti-TNF prior to the primary surgery. Eventually 5 of these 16 patients underwent a second resection of the neoterminal ileum.
Complications
In total, there were 11 patients with postoperative complications in need of a re-intervention. Of these patients, three required radiological intervention with percutaneous drainage of an intra-abdominal abscess. In the other eight patients, surgical re-intervention was required due to anastomotic leakage (n = 5), an intra- abdominal abscess (n = 2) or bleeding (n = 1).There were no significant differences in number of fistulas, complications that needed re-intervention, conversion to open surgery and stoma creation between the groups with or without anti-TNF (Table 3) .
Discussion
This study demonstrated that over time patients were treated more intensively with different types of drug combinations. As a result, the time interval from initial diagnosis to surgery increased. The optimization of medical treatment protocols did not result in more limited resections throughout the years as is sometimes argued as one of the benefits of extensive treatment.
The overall median time from diagnosis to ileocolic resection was 39.0 months. In a recent study from Canada by Fu et al. evaluating the impact of medical therapy on CD patients in a tertiary referral centre between 1995 and 2010, a median time from diagnosis to resection of 72 months was observed [6] . In accordance with the present study, these authors also observed a significant difference in time from diagnosis to surgery in patients treated with anti-TNF (n = 38) compared to patients without anti-TNF (n = 76) between 2005 and 2010 (mean 90 vs 48 months, P = 0.02) [6] .
The medical therapy step-up approach did not result in more limited resections when it came to surgery in the present study. In a retrospective study by Tielbeek IQR, interquartile range; TNF, tumour necrosis factor. *Denominator indicates the number of patients for whom this information was known. †Complications that needed surgical or radiological intervention. ‡Only for laparoscopic surgery. Table 4 Comparison of patients who underwent an ileocolic resection in the biological era in the present study and the population-based study. et al. no improvement of the inflammatory activity score on serial MRI scans was found in patients with CD who did not respond to anti-TNF therapy after a median follow-up of 151 weeks (56-179). In addition, no reduction in length of inflammation in clinical nonresponders was observed (decrease from 15.6 to 15.6 cm, P = 0.98) [7] . In the previously mentioned study by Fu et al., no significant difference in the length of resected small bowel was found in patients treated with anti-TNF vs patients without anti-TNF (mean 23.0 vs 21.5 cm, P = 0.92) [6] .
In the present study, anti-TNF use increased significantly over time since the introduction of infliximab in 1999. In this period, immunomodulatory use increased also. This has been observed in other studies [3, 8] . Timely surgery in patients who do not respond to optimal medical therapy will prevent complications, e.g. progressive enteral fistulization. In the literature, preoperative as well as postoperative complications of anti-TNF are described, e.g. significantly increased rates of small bowel fistula repair, postoperative infections and anastomotic related complications [9, 10] . The proportion of patients with perforating disease (27.3%) in the present study is relatively low compared to the 43.9% perforating disease reported in a meta-analysis [6] . In addition, there was no significant difference in the number of fistulas between the groups with and without anti-TNF, suggesting that the threshold for the gastroenterologist to refer the patient to the surgeon is relatively low with adequate discussion of patients in a multidisciplinary team. Although the proportion of postoperative complications requiring re-intervention in the present study was twice as high in the patient group with anti-TNF, there was no significant difference and overall numbers were small. This study has some limitations: first its retrospective design; second the fact that the patient group represents a tertiary referral centre population and might not be representative for all patients. However, after comparison with data from non-academic IBD patients treated in the catchment area of this tertiary referral centre, it seems reasonable to assume that this patient group reflects a representative background population. Furthermore, it remains unclear how many patients avoided surgery by being on anti-TNF therapy in this study. Due to the design of the population-based study, Figure 4 Correlation between the length (in cm) of resected ileum and the date of ileocolic resection for Crohn's disease stratified for type of operation. Spearman correlation coefficient À0.11, P = 0.14. Linear regression À0.28 (95% CI: À0.72 to 0.16), P = 0.21.
Colorectal Disease ª 2016 The Association of Coloproctology of Great Britain and Ireland. 19, 551-558 patients were included between 2004 and 2010; it was not possible to comment on the number of patients going to surgery over a longer period of time. Therefore it remains debatable whether the introduction of immunomodulators and anti-TNF therapy has had a direct effect on the risk of surgery among patients with CD of the terminal ileum. The previously mentioned study by Rungoe et al. did find a significant decrease of surgery rates along with an increased risk of surgery among users of medication prescribed within the first year of diagnosis [3] . This is in accordance with other studies [11, 12] . Another possible drawback is that there might have been some variations in the way the surgeons and gastroenterologists have treated their patients throughout the years irrespective of medical treatment.
In conclusion, CD patients who had surgery for terminal ileitis were treated more intensively with medication since the introduction of anti-TNF. Time from diagnosis to surgery increased since the introduction of anti-TNF in the treatment algorithm of ileocolic CD, while the extent of the ileocolic resection did not change.
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